
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
For the 4th year, experts weigh in on key sessions from one of pediatrics premier gatherings. Here are highlights and insights on why they matter.
Directs to tag page






